Medwire 
(10/11, Robertson) reports, "Urinary adiponectin may provide a novel biomarker for diabetic nephropathy," according to a study presented at the European Association for the Study of Diabetes 48th Annual Meeting. Researchers said, "Urinary adiponectin seems to be as good as albumin excretion rate (AER) in predicting the progress from macroalbuminuria to end stage renal disease (ESRD) in patients with type 1 diabetes." The investigators, "in a study conducted as part of the Finnish Diabetic Nephropathy Study and including 2201 patients...found that 101 of 1451 patients with a normal AER progressed to microalbuminuria, 42 of 319 progressed from micro- to macroalbuminuria, and 71 of 320 progressed from macroalbuminuria to end-stage renal disease (ESRD), over a median follow-up period of 5.8 years."
(10/11, Robertson) reports, "Urinary adiponectin may provide a novel biomarker for diabetic nephropathy," according to a study presented at the European Association for the Study of Diabetes 48th Annual Meeting. Researchers said, "Urinary adiponectin seems to be as good as albumin excretion rate (AER) in predicting the progress from macroalbuminuria to end stage renal disease (ESRD) in patients with type 1 diabetes." The investigators, "in a study conducted as part of the Finnish Diabetic Nephropathy Study and including 2201 patients...found that 101 of 1451 patients with a normal AER progressed to microalbuminuria, 42 of 319 progressed from micro- to macroalbuminuria, and 71 of 320 progressed from macroalbuminuria to end-stage renal disease (ESRD), over a median follow-up period of 5.8 years."
No comments:
Post a Comment